Literature DB >> 2868701

Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. II. Role of neuroleptic treatment, attention, and mental effort.

K F Berman, R F Zec, D R Weinberger.   

Abstract

We conducted two xenon Xe 133 inhalation regional cerebral blood flow (rCBF) studies to clarify earlier findings of dorsolateral prefrontal cortex (DLPFC) dysfunction in medication-free patients with chronic schizophrenia. In the first study, 24 neuroleptic-treated patients and 25 normal controls underwent three rCBF procedures, first while at rest, then during the Wisconsin Card Sort (WCS), which tests DLPFC cognitive function, and during a number-matching task that controlled for aspects of the WCS-rCBF experience not specifically related to DLPFC. The results were qualitatively identical to those previously reported for medication-free patients. In the second study, rCBF was determined while 18 medication-free patients and 17 normal control subjects each performed two versions of a visual continuous performance task (CPT). No differences in DLPFC blood flow between the two groups were found during either CPT condition. These data suggest that DLPFC dysfunction in schizophrenia is independent of medication status and not determined simply by state factors such as attention, mental effort, or severity of psychotic symptoms. Dysfunction of DLPFC appears to be a cognitively linked physiologic deficit in this illness.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2868701     DOI: 10.1001/archpsyc.1986.01800020032005

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  52 in total

1.  Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia.

Authors:  Frank A Middleton; Karoly Mirnics; Joseph N Pierri; David A Lewis; Pat Levitt
Journal:  J Neurosci       Date:  2002-04-01       Impact factor: 6.167

Review 2.  The role of prefrontal cortex in working-memory capacity, executive attention, and general fluid intelligence: an individual-differences perspective.

Authors:  Michael J Kane; Randall W Engle
Journal:  Psychon Bull Rev       Date:  2002-12

Review 3.  [Genetic and pharmacological effects on prefrontal cortical function in schizophrenia].

Authors:  Andreas Heinz; Dieter F Braus; Berenice Romero; Jürgen Gallinat; Imke Puls; Georg Juckel; Daniel R Weinberger
Journal:  Nervenarzt       Date:  2004-09       Impact factor: 1.214

4.  Modulation of basolateral amygdala neuronal firing and afferent drive by dopamine receptor activation in vivo.

Authors:  J A Rosenkranz; A A Grace
Journal:  J Neurosci       Date:  1999-12-15       Impact factor: 6.167

Review 5.  Neuroimaging of cognitive disability in schizophrenia: search for a pathophysiological mechanism.

Authors:  J D Ragland; J Yoon; M J Minzenberg; C S Carter
Journal:  Int Rev Psychiatry       Date:  2007-08

6.  Meta-analysis of neuroimaging studies of the Wisconsin card-sorting task and component processes.

Authors:  Bradley R Buchsbaum; Stephanie Greer; Wei-Li Chang; Karen Faith Berman
Journal:  Hum Brain Mapp       Date:  2005-05       Impact factor: 5.038

7.  Prefrontal serotonin depletion affects reversal learning but not attentional set shifting.

Authors:  H F Clarke; S C Walker; H S Crofts; J W Dalley; T W Robbins; A C Roberts
Journal:  J Neurosci       Date:  2005-01-12       Impact factor: 6.167

8.  Nonsocial and social cognition in schizophrenia: current evidence and future directions.

Authors:  Michael F Green; William P Horan; Junghee Lee
Journal:  World Psychiatry       Date:  2019-06       Impact factor: 49.548

9.  Morphometry of the corpus callosum in monozygotic twins discordant for schizophrenia: a magnetic resonance imaging study.

Authors:  M F Casanova; R D Sanders; T E Goldberg; L B Bigelow; G Christison; E F Torrey; D R Weinberger
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-05       Impact factor: 10.154

Review 10.  Plasticity at hippocampal to prefrontal cortex synapses is impaired by loss of dopamine and stress: importance for psychiatric diseases.

Authors:  Thérèse M Jay; Cyril Rocher; Maïte Hotte; Laurent Naudon; Hirac Gurden; Michael Spedding
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.